Literature DB >> 17005804

Biofilm formation by the emerging fungal pathogen Trichosporon asahii: development, architecture, and antifungal resistance.

Giovanni Di Bonaventura1, Arianna Pompilio, Carla Picciani, Manuela Iezzi, Domenico D'Antonio, Raffaele Piccolomini.   

Abstract

Trichosporon asahii is the most common cause of fatal disseminated trichosporonosis, frequently associated with indwelling medical devices. Despite the use of antifungal drugs to treat trichosporonosis, infection is often persistent and is associated with high mortality. This drove our interest in evaluating the capability of T. asahii to form a biofilm on biomaterial-representative polystyrene surfaces through the development and optimization of a reproducible T. asahii-associated biofilm model. Time course analyses of viable counts and a formazan salt reduction assay, as well as microscopy studies, revealed that biofilm formation by T. asahii occurred in an organized fashion through four distinct developmental phases: initial adherence of yeast cells (0 to 2 h), germination and microcolony formation (2 to 4 h), filamentation (4 to 6 h), and proliferation and maturation (24 to 72 h). Scanning electron microscopy and confocal scanning laser microscopy revealed that mature T. asahii biofilms (72-h) displayed a complex, heterogeneous three-dimensional structure, consisting of a dense network of metabolically active yeast cells and hyphal elements completely embedded within exopolymeric material. Antifungal susceptibility testing demonstrated a remarkable rise in the MICs of sessile T. asahii cells against clinically used amphotericin B, caspofungin, voriconazole, and fluconazole compared to their planktonic counterparts. In particular, T. asahii biofilms were up to 16,000 times more resistant to voriconazole, the most active agent against planktonic cells (MIC, 0.06 microg/ml). Our results suggest that the ability of T. asahii to form a biofilm may be a major factor in determining persistence of the infection in spite of in vitro susceptibility of clinical isolates.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17005804      PMCID: PMC1610057          DOI: 10.1128/AAC.00556-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  29 in total

Review 1.  A case of Trichosporon beigelii endocarditis.

Authors:  M Y Mooty; S S Kanj; M Y Obeid; G Y Hassan; G F Araj
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2001-02       Impact factor: 3.267

Review 2.  Microbial biofilms: from ecology to molecular genetics.

Authors:  M E Davey; G A O'toole
Journal:  Microbiol Mol Biol Rev       Date:  2000-12       Impact factor: 11.056

3.  In vitro antifungal susceptibilities of Trichosporon species.

Authors:  Niki I Paphitou; Luis Ostrosky-Zeichner; Victor L Paetznick; Jose R Rodriguez; Enuo Chen; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2002-04       Impact factor: 5.191

Review 4.  Infections due to emerging and uncommon medically important fungal pathogens.

Authors:  T J Walsh; A Groll; J Hiemenz; R Fleming; E Roilides; E Anaissie
Journal:  Clin Microbiol Infect       Date:  2004-03       Impact factor: 8.067

5.  Contributions to a revision of the genus Trichosporon.

Authors:  E Guého; M T Smith; G S de Hoog; G Billon-Grand; R Christen; W H Batenburg-van der Vegte
Journal:  Antonie Van Leeuwenhoek       Date:  1992-05       Impact factor: 2.271

6.  Basic features of biofilms--why are they difficult therapeutic targets?

Authors:  Gary C Armitage
Journal:  Ann R Australas Coll Dent Surg       Date:  2004-10

7.  Transmission of Trichosporon asahii oesophagitis by a contaminated endoscope.

Authors:  C Lo Passo; I Pernice; A Celeste; G Perdichizzi; F Todaro-Luck
Journal:  Mycoses       Date:  2001       Impact factor: 4.377

8.  Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance.

Authors:  J Chandra; D M Kuhn; P K Mukherjee; L L Hoyer; T McCormick; M A Ghannoum
Journal:  J Bacteriol       Date:  2001-09       Impact factor: 3.490

Review 9.  Trichosporonosis in patients with neoplastic disease.

Authors:  T J Walsh; K R Newman; M Moody; R C Wharton; J C Wade
Journal:  Medicine (Baltimore)       Date:  1986-07       Impact factor: 1.889

10.  In vitro activity of voriconazole against selected fungi.

Authors:  M R McGinnis; L Pasarell; D A Sutton; A W Fothergill; C R Cooper; M G Rinaldi
Journal:  Med Mycol       Date:  1998-08       Impact factor: 4.076

View more
  54 in total

1.  Photodynamic inactivation of biofilms formed by Candida spp., Trichosporon mucoides, and Kodamaea ohmeri by cationic nanoemulsion of zinc 2,9,16,23-tetrakis(phenylthio)-29H, 31H-phthalocyanine (ZnPc).

Authors:  J C Junqueira; A O C Jorge; J O Barbosa; R D Rossoni; S F G Vilela; A C B P Costa; F L Primo; J M Gonçalves; A C Tedesco; J M A H Suleiman
Journal:  Lasers Med Sci       Date:  2012-01-26       Impact factor: 3.161

2.  In Vitro Activity of Berberine Alone and in Combination with Antifungal Drugs Against Planktonic Forms and Biofilms of Trichosporon Asahii.

Authors:  Lin Cong; Yong Liao; Suteng Yang; Rongya Yang
Journal:  Mycopathologia       Date:  2017-01-31       Impact factor: 2.574

Review 3.  Diversity of experimental designs for the fabrication of antifungal surfaces for the built environment.

Authors:  Arturo Aburto-Medina; Phuc Hoang Le; Shane MacLaughlin; Elena Ivanova
Journal:  Appl Microbiol Biotechnol       Date:  2021-03-11       Impact factor: 4.813

Review 4.  Fungi in the Wound Microbiome.

Authors:  Lindsay Kalan; Elizabeth A Grice
Journal:  Adv Wound Care (New Rochelle)       Date:  2018-07-01       Impact factor: 4.730

5.  Fatal Disseminated Infection by Trichosporon asahii Under Voriconazole Therapy in a Patient with Acute Myeloid Leukemia: A Review of Breakthrough Infections by Trichosporon spp.

Authors:  I Ramírez; D Moncada
Journal:  Mycopathologia       Date:  2019-12-18       Impact factor: 2.574

6.  In vitro activities of antifungal combinations against biofilms and planktonic forms of clinical Trichosporon asahii isolates.

Authors:  Yong Liao; Suteng Yang; Lin Cong; Xuelian Lu; Junhong Ao; Rongya Yang
Journal:  Antimicrob Agents Chemother       Date:  2014-09-22       Impact factor: 5.191

Review 7.  Fungal biofilms, drug resistance, and recurrent infection.

Authors:  Jigar V Desai; Aaron P Mitchell; David R Andes
Journal:  Cold Spring Harb Perspect Med       Date:  2014-10-01       Impact factor: 6.915

8.  Molecular Identification, Genotyping, Phenotyping, and Antifungal Susceptibilities of Medically Important Trichosporon, Apiotrichum, and Cutaneotrichosporon Species.

Authors:  Elaine Patrícia Tavares do Espírito Santo; Ruan Campos Monteiro; Ana Roberta Fusco da Costa; Silvia Helena Marques-da-Silva
Journal:  Mycopathologia       Date:  2019-11-27       Impact factor: 2.574

9.  The development of animal infection models and antifungal efficacy assays against clinical isolates of Trichosporon asahii, T. asteroides and T. inkin.

Authors:  Marçal Mariné; Vinicius Leite Pedro Bom; Patricia Alves de Castro; Lizziane Kretli Winkelstroter; Leandra Naira Ramalho; Neil Andrew Brown; Gustavo Henrique Goldman
Journal:  Virulence       Date:  2015-03-09       Impact factor: 5.882

10.  Biofilm formation by Pneumocystis spp.

Authors:  Melanie T Cushion; Margaret S Collins; Michael J Linke
Journal:  Eukaryot Cell       Date:  2008-09-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.